Abstract Sumatriptan and the newer triptans (zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan, frovatriptan and donitriptan) display high agonist activity at 5-HT 1B and 5-HT 1D receptors. Most triptans, but not all (donitriptan, frovatriptan and rizatriptan), also have a high affinity at the 5-ht 1F receptor. In anaesthetised animals, triptans decrease the arteriovenous anastomotic fraction of carotid blood flow. In isolated blood vessels, triptans cause contraction and this effect is more marked on cranial arteries. The 5-HT 1B receptors and not 5-HT 1D or 5-ht 1F receptors mediate the vasocontrictor effect of triptans. In animal studies, the triptans exert an inhibitory effect within the trigeminovascular system. The therapeutic effect of triptans is mediated mainly by their cranial vasoconstrictor property. Whether the inhibitory effects of the triptans on the trigeminovascular system contribute to their efficacy in migraine is still a moot point. The biggest success of triptans is that they provide an excellent therapeutic option for migraine therapy. This success has generated awareness for migraine in patients, clinicians and researchers alike. This, in turn, has increased our knowledge of the disease pathophysiology, which will ultimately lead to even better drugs in future. Among the failures of triptans, one may mention that a minority of patients respond poorly and others may have headache recurrence and chest symptoms. Overall, however, the advantages of triptans far outweigh their disadvantages and they represent a significant advance in medical therapy. increases internal carotid and middle cerebral artery blood flow velocities in migraine patients [7, 8] . Investigations in anaesthetised animals show that sumatriptan as well as other triptans exclusively decrease the arteriovenous anastomotic fraction of carotid blood flow [5, 6] . The role of 5-HT 1B and 5-HT 1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses has been investigated by using SB224289 and BRL15572, which have a selective antagonist activity at cloned human 5-HT 1B and 5-HT 1D receptors, respectively [9] [10] [11] . SB224289, but not BRL15572 antagonises the effects of sumatriptan (Fig.  2 ) [12] . Despite the fact that our recent investigation revealed that BRL15572, has a low affinity for the porcine 5-HT 1D receptor in contrast to the human 5-HT 1D receptor [13] , it is obvious that the 5-HT 1B receptor mediates carotid vasoconstrictor response. A number of isolated blood vessels from several species contracts in response to triptans, but the contractile effect is more marked on cranial vessels. There is ample evidence that this effect is mediated by the 5-HT 1B receptor and not by 5-HT 1D or 5-ht 1F receptors [14] [15] [16] .
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Inhibition of the trigeminovascular system
Triptans interfere with the trigeminovascular system, at both the peripheral and central levels. Thus, they inhibit plasma protein extravasation, calcitonin gene-related peptide (CGRP) release and dural vasodilatation following trigeminal ganglion stimulation; they also inhibit neuronal activity in trigeminal nucleus caudalis following stimulation of sagittal sinus or dural vessels (reviewed in [5] ). Unlike more lipophilic triptans, sumatriptan does not enter the central nervous system and, therefore, fails to affect c-fos mRNA expression in the trigeminal nucleus caudalis following trigeminal ganglion stimulation in rats [17] . In view of excellent therapeutic action of sumatriptan (see subsequent section), one can question whether central trigeminal inhibition is predictive of antimigraine potential.
Pharmacokinetics of triptans
The pharmacokinetic characteristics of triptans are presented in Table 2 . Subcutaneous sumatriptan (6 mg) is quickly absorbed with a t max of approximately 10 min and an average bioavailability of 96%. After oral administration of therapeutic doses (100 mg) of sumatriptan, the t max is substantially delayed (1.5 h) and, more importantly, the bioavailability is rather low (~14%). Intranasal or rectal administration of sumatriptan does not seem to improve these parameters much. The oral bioavailability of newer triptans is much improved. This can be partly attributed to the more lipophilic nature of these drugs. Interestingly, the t max after oral administration of zolmitriptan, naratriptan, eletriptan, almotriptan and frovatriptan is not much better, for some even worse, than that of sumatriptan, whereas rizatriptan seems to reach its peak plasma levels quicker compared to sumatriptan. The unbound C max values (C max corrected for plasma protein binding) of newer triptans are lower than that of sumatriptan. This is apparently due to two main factors: lower therapeutic concentrations are needed as these drugs have a higher affinity at 5-HT 1B/1D receptors and these drugs have been better titrated, thus reducing therapeutic penalty.
With the exception of rizatriptan, the newer triptans are degraded slower than sumatriptan. Especially frovatriptan has a plasma half-life of 26-30 h, but it is uncertain that headache recurrence is lower with frovatriptan, and low sub-therapeutic concentrations of a drug may not be related to its effects on recurrence. In contrast to sumatriptan and naratriptan, active metabolites have been reported for zolmitriptan, rizatriptan and eletriptan. It is not known whether and, if so, to what extent the metabolites contribute towards therapeutic activity.
Success of triptans
Excellent therapeutic option
The advent of sumatriptan, followed by other triptans, has provided an excellent therapeutic option for migraine patients. As depicted in Fig. 3 , the mean therapeutic gain for headache relief achieved with triptans is high; 6 mg subcu- taneous sumatriptan is the most effective. This analysis indicates that 80 mg eletriptan concerning headache relief at 2 hours is superior to 100 mg sumatriptan, and that 2.5 mg naratriptan and 2.5 mg frovatriptan are inferior to 100 mg sumatriptan. All other triptans or doses of oral triptans seem roughly equivalent to 50-100 mg sumatriptan. Intranasal and rectal sumatriptan seem equivalent to oral sumatriptan [5, 6] .
Awareness for migraine in patients, clinicians and researchers
The availability of triptans has undoubtedly heightened awareness for migraine in patients, clinicians and researchers alike. There is much more understanding for the disease today than before the triptan era. Obviously, the market for antimigraine drugs has expanded as never before and this has resulted in serious drug development programmes being undertaken by pharmaceutical companies. The results are already there in terms of the growing number of triptans available to physicians and consumers.
Better understanding of the pathophysiology of migraine
The increased awareness in migraine and the availability of triptans as analytical tools have indirectly helped our understanding of migraine. It is now generally believed that migraine is a channelopathy (probably genetically determined) [18] , which triggers a central 'generator' to initiate an attack along the process depicted in Fig. 4 (explained in De Vries et al. [19] ). Triptans (and ergot alkaloids) abort migraine attack primarily via constriction of dilated cranial extracerebral blood vessels. Although the triptans reduce neuropeptide release and plasma protein extravasation across dural vessels [20, 21] and inhibit impulse transmission centrally within the trigeminovascular system [22, 23] , the contribution of neuronal effects in the therapeutic action is yet uncertain. Nonetheless, the increasing number of novel experimental models for migraine [19] may lead to the development of antimigraine drugs that are devoid of vasocontrictor action (Fig. 4) . Some attempts have indeed failed [24] . However, in view of the possible involvement of CGRP in migraine pathophysiology [25] [26] [27] [28] , antagonism of CGRP receptors is an interesting approach for discovering a cardiovascular-safe antimigraine drug. Doods et al. [29] have Dose of triptans (mg) Fig. 3 Mean therapeutic gain (proportion of patients responding to active drug minus proportion of patients responding to placebo) and 95% confidence intervals for different doses of sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. All triptans were administered orally, except sumatriptan for which nasal (N), rectal (R) and subcutaneous (S) routes were also employed. Note that the therapeutic gain was determined with most certainty for 100 mg sumatriptan, 6 mg subcutaneous sumatriptan and 10 mg rizatriptan (approximately, 4500, 3000 and 3500 patients, respectively).
(Modified from [5, 6]) recently described a dipeptide compound, BIBN4096BS, which is a potent and selective CGRP receptor antagonist. BIBN4096BS is presently under clinical investigation and the results of the phase IIa trials are awaited with great interest.
Failure of triptans
Triptan-resistant patients A minority of patients does not respond to oral triptans. The non-responders are much less with parenteral sumatriptan. The exact reason for triptan-resistance is not known, but genetic variability in the receptors may be one aspect.
Slow headache relief and high headache recurrence
In some patients, the headache relief may not be quick enough and in others after initial relief the headache may reappear. Although the exact causes for slow headache relief and high headache recurrence are not known, a relatively long t max for oral triptans in combination with short t 1/2 may be involved in specific patients.
Chest symptoms and coronary artery constriction
There is obviously a concern about the contractile effect of triptans on the human coronary artery (reviewed by MaassenVanDenBrink et al. [30] ). However, this effect of triptans is fortunately much weaker than that on human cerebral vessels [5, 6] . As exemplified in Figs. 5 and 6, based on the concentration response curves in isolated human blood vessels, the predicted contraction in patients following a therapeutic dose of sumatriptan and eletriptan is much more in the middle menigeal artery than in the coronary artery or saphenous vein [31] . Therefore, the triptans are not expected to cause myocardial ischaemia in migraine patients without any coronary artery affliction.
However, these drugs must remain contraindicated in patients with stenosed or hyperreactive coronary arteries [30, 31] .
Conclusions
Overall, despite some shortcomings, the triptans represent an excellent option in the therapy of migraine. 
